GlassScriptPhysician profile
Arvind K Maheshwari
NPI 1659767903
$3,703.15
in general payments reported to CMS, 2019-2025
18 companies · $1,722 in 2025
The $1,722 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2022: $346 · 2023: $1,309 · 2024: $85.80 · 2025: $1,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,174 · Consulting Fee: $900 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.10 |
| Consulting Fee | $900.00 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $1,172.64 | 2025 | Strensiq |
| Corcept Therapeutics | $829.46 | 2019-2025 | Korlym |
| Lilly USA, LLC | $294.36 | 2022-2023 | Jardiance, Mounjaro, Trulicity |
| Abbott Laboratories | $187.68 | 2022-2023 | Freestyle Libre 3 |
| Antares Pharma, INC. | $172.22 | 2023 | Tlando, Nocdurna, Xyosted |
| Abbvie INC. | $156.86 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.27 | 2022-2023 | Jardiance, Tradjenta |
| Sanofi-Aventis U.S. LLC | $149.98 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $149.16 | 2019-2023 | Farxiga |
| Xeris Pharmaceuticals, INC. | $85.80 | 2024 | Recorlev |
| Amneal Pharmaceuticals LLC | $78.04 | 2022-2023 | Unithroid |
| Cardiva Medical, INC. | $73.57 | 2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Amgen INC. | $45.26 | 2022-2023 | Prolia, Evenity |
| Mannkind Corporation | $42.50 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.36 | 2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $37.28 | 2023 | Signifor Lar, Isturisa |
| Ibsa Pharma INC. | $21.12 | 2023 | Tirosint, Licart |
| Tandem Diabetes Care, INC. | $14.59 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Maheshwari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.